Request for Covid-19 Impact Assessment of this Report
Market Dynamics
The rapidly growing incidences of cardiac disorders along with demand for minimally invasive treatment due to less complication, changing lifestyle and rise in older population are the prime drivers for the interventional cardiology devices market. Moreover, increasing awareness among the patient population in developing countries along with favorable government initiatives and technical advancements has led to the increased importance of this market.
The high cost of the devices, many entry barriers, and stringent government policies put constraints on the market.
Market Segmentation
The market is segmented by type of products (Catheters, Balloons (Scoring balloons, Cutting balloons and Drug Eluting balloons), Stents (Bare Metal stents, Drug Eluting Stents and Bioresorbable Stents), Guidewires, Vascular Closure Devices and Atherectomy Devices), by end users (ASCs, Hospitals, Physicians' office) and by region (North America, Europe, Asia-Pacific and the Rest of the World).
Geographic Analysis
North America leads the interventional cardiology devices market followed by Europe. Moreover, Asia-Pacific region is expected to grow rapidly due to rising population and technological development.
Key Players
Some of the major players in the market include Abbott Vascular, Boston Scientific, Cordis, Medtronic, St. Jude Medical and Lombard Medical Inc.
The report contains comprehensive analysis on:
--> Interventional Cardiology Devices Market Segments
--> Interventional Cardiology Devices Market Drivers, Restraints and Opportunities
--> Interventional Cardiology Devices Market Size & Forecast 2016 to 2022
--> Supply & Demand Value Chain
--> Interventional Cardiology Devices Market Current Trends
--> Competition & Major Companies
--> Technology and R&D Status
--> Porters Five Force Analysis
--> Strategic and Critical Success Factor Analysis of Key Players
Regional analysis for Interventional Cardiology Devices Market includes
--> North America
>> US and Canada
--> Latin America
>> Mexico, Brazil, Argentina and Rest of Latin America
--> Western Europe
>> EU5 (Germany, France, Italy, Spain, U.K.)
>> Nordic Countries (Denmark, Finland, Norway, and Sweden)
>> Benelux (Belgium, The Netherlands, and Luxembourg)
>> Rest of Western Europe
--> Eastern Europe
>> Russia
>> Poland
>> Rest of Eastern Europe
--> Asia Pacific
>> China
>> India
>> Japan
>> Australia and New Zealand
>> Rest of Asia Pacific
--> Middle East and Africa
>> GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
>> South Africa
>> North Africa
>> Rest of Middle East and Africa
This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides in-depth market segmentation that is derived from extensive product mapping exercises, macro-economic factors and other qualitative and quantitative insights. The impact of all such factors are delivered across multiple market segments and geographies.
Report Highlights::
--> Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
--> Consumer and Pricing Analysis
--> Market dynamics of the industry
--> In-depth Market Segmentation
--> Historical and Projected Market Sizing in terms of volume and value
--> Recent market trends and Impact Factors
--> R&D Status and Technology Overview
--> Extensive Industry Structure Coverage
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...